Gritstone bio Dirección

Dirección controles de criterios 2/4

El CEO de Gritstone bio es Andrew Allen , nombrado en Aug 2015, tiene una permanencia de 9.25 años. compensación anual total es $3.44M, compuesta por 18.8% salario y 81.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.53% de las acciones de la empresa, por valor de €53.60K. La antigüedad media del equipo directivo y de la junta directiva es de 3.7 años y 6.5 años, respectivamente.

Información clave

Andrew Allen

Chief Executive Officer (CEO)

US$3.4m

Compensación total

Porcentaje del salario del CEO	18.8%
Permanencia del CEO	9.3yrs
Participación del CEO	1.5%
Permanencia media de la dirección	3.7yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrew Allen en comparación con los beneficios de Gritstone bio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$133m
Mar 31 2024	n/a	n/a	-US$145m
Dec 31 2023	US$3m	US$646k	-US$138m
Sep 30 2023	n/a	n/a	-US$139m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$620k	-US$120m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$116m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$589k	-US$75m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$2m	US$569k	-US$105m
Sep 30 2020	n/a	n/a	-US$106m
Jun 30 2020	n/a	n/a	-US$107m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$2m	US$533k	-US$94m
Sep 30 2019	n/a	n/a	-US$84m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$475k	-US$65m
Sep 30 2018	n/a	n/a	-US$65m
Jun 30 2018	n/a	n/a	-US$56m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$592k	US$436k	-US$41m

Compensación vs. Mercado: La compensación total de Andrew($USD3.44M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD474.54K).

Compensación vs. Ingresos: La compensación de Andrew ha aumentado mientras la empresa no es rentable.

CEO

Andrew Allen (58 yo)

9.3yrs

Permanencia

US$3,444,071

Compensación

Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph D., serves as Independent Director at Verge Analytics, Inc. since September 2021. He has also held clinical development leadership positions at Chiron Corpo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Allen	Co-Founder	9.3yrs	US$3.44m	1.53% € 53.6k
Erin Jones	Executive VP & COO	3.7yrs	US$1.52m	0.063% € 2.2k
Karin Jooss	Executive VP and Head of Research & Development	3.7yrs	US$1.58m	0.39% € 13.6k
Vassiliki Economides	Executive VP & CFO	3.4yrs	sin datos	0.059% € 2.1k
James Cho	Chief Accounting Officer	3.8yrs	sin datos	0.070% € 2.4k
George MacDougall	Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Stacy Proctor	Executive VP & Chief People Officer	3.3yrs	sin datos	sin datos
Matthew Hawryluk	Executive VP & Chief Business Officer	9yrs	sin datos	0.034% € 1.2k

3.7yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2JQ se considera experimentado (3.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Allen	Co-Founder	9.3yrs	US$3.44m	1.53% € 53.6k
Elaine Jones	Independent Chairman of the Board	5.2yrs	US$176.00k	0% € 0
Stephen Webster	Independent Director	less than a year	sin datos	0.021% € 739.8
Lawrence Corey	Independent Director	2.3yrs	US$132.50k	0% € 0
Timothy Chan	Member of Scientific Advisory Board	7.4yrs	sin datos	sin datos
Eugene Zhukovsky	Member of Scientific Advisory Board	5.6yrs	sin datos	0% € 0
Graham Lord	Member of Scientific Advisory Board	7.4yrs	sin datos	sin datos
Naiyer Rizvi	Independent Director & Member of Scientific Advisory Board	8.4yrs	US$140.00k	0% € 0
James Gulley	Member of Scientific Advisory Board	7.4yrs	sin datos	sin datos
Alessandro Sette	Member of Scientific Advisory Board	7.4yrs	sin datos	sin datos
Shefali Agarwal	Independent Director	3.4yrs	US$138.50k	0% € 0
Clare Fisher	Independent Director	2.8yrs	US$136.50k	sin datos

6.5yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2JQ se considera experimentada (6.5 años de antigüedad promedio).

Gritstone bio Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.31 loss in 2Q 2023)

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Full year 2023 earnings released: US$1.20 loss per share (vs US$1.32 loss in FY 2022)

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2022)

New major risk - Financial position

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.32 loss per share (vs US$0.95 loss in FY 2021)

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in 3Q 2021)

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 2Q 2021)

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.16 profit in 1Q 2021)

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Less than half of directors are independent

Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19

Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

Gritstone Bio, Inc. Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.69 loss in 2Q 2020)

High number of new directors

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Growth Index

First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020)

Full year 2020 earnings released: US$2.79 loss per share (vs US$2.81 loss in FY 2019)

Revenue beats expectations

Gritstone Oncology, Inc. Announces Promotions Within its Leadership Team

Gritstone Oncology, Inc Announces Board Appointments

Executive VP & CTO recently sold €182k worth of stock

Gritstone Oncology, Inc. and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

Gritstone Oncology, Inc. Advances Development of Second Generation Vaccine Against SARS-CoV-2

New 90-day high: €4.70

Gritstone Oncology, Inc. announced that it expects to receive $15.000001 million in funding

New 90-day high: €3.34

Gritstone Oncology, Inc. announced that it expects to receive $110 million in funding from Avidity Partners Management LP, EcoR1 Capital, LLC, Redmile Group, LLC, and other investors

Gritstone Oncology, Inc Announces Resignation of Jean-Marc Bellemin as Chief Financial Officer

New 90-day low: €2.16

Third quarter 2020 earnings released: US$0.69 loss per share

Revenue misses expectations

Gritstone Oncology, Inc. Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE

New 90-day low: €2.32

Gritstone Oncology, Inc.(NasdaqGS:GRTS) dropped from S&P Global BMI Index